← Back to Search

MSTEP for Multiple Sclerosis (MStep Trial)

N/A
Waitlist Available
Led By Nancy E Mayo, PhD
Research Sponsored by McGill University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
Awards & highlights

MStep Trial Summary

Despite the benefits of exercise and physical activity people with Multiple Sclerosis (MS) are relatively inactive. Physical activity is important for persons with disabilities to maintain physical function. A lack of physical activity can contribute to heart disease, osteoporosis, obesity, and diabetes. At the moment, the best way for people with MS to exercise and be physical activity is unknown. People with MS report not knowing what to do. This is a barrier to exercise. The global aim of this study is to contribute evidence for the role of targeted exercise in altering MS outcomes over time. The design is a randomized controlled trial (RCT). The primary research question is to what extent does an MS Tailored Exercise Program (MSTEP) result in greater improvements in exercise capacity and related outcomes in comparison to a program based on general guidelines for exercise among people with MS who are sedentary and wish to engage in exercise as part of MS self-management. The primary outcome for this question is exercise capacity measured using cycle ergometry. However exercise efficiency, functional ambulation, strength, components of quality of life including frequency and intensity of fatigue symptoms, mood, global physical function, health perception, and illness intrusiveness, will also be measured as components of a global response outcome. The first confirmatory hypothesis is that MSTEP will result in a greater proportion of people making clinically relevant gains (at least 10% change) in exercise capacity than with general guidelines after 12 months of intervention; a secondary hypothesis is that, while there may be some decline in exercise capacity among individuals from end of intervention to follow-up one year later, the decline will be greater in the general guideline group augmenting the difference between groups in the proportion making 10% change from study entry to 24 months. In other words, gains will be maintained more for the MSTEP group over the general guideline group. An exploratory hypothesis is that more of the targeted outcomes will improve with the MSTEP program than the general guideline approach. An explanatory hypothesis is that these gains will be accompanied by reports of greater exercise enjoyment and exercise self-efficacy (confidence) with the MSTEP program than with the general guideline program leading to more consistent exercise engagement and improved long-term adherence.

Eligible Conditions
  • Multiple Sclerosis

MStep Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 timepoints: at baseline, at 6 months, at 12 months, at 18 months, at 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
oxygen consumption
Secondary outcome measures
6 Minute Walk test (6MWT)
Anaerobic leg power
Change in fatigue levels
+8 more

MStep Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: MSTEPExperimental Treatment1 Intervention
The MSTEP program is a 6 day tailored exercise program. It includes flexibility, aerobic, peripheral strengthening, core and balance training, power and speed training and push days.
Group II: General guideline approachActive Control1 Intervention
The general Guideline approach is the general guidelines that are recommended for people with MS by the Canadian Society Exercise Physiology.

Find a Location

Who is running the clinical trial?

McGill UniversityLead Sponsor
395 Previous Clinical Trials
999,137 Total Patients Enrolled
6 Trials studying Multiple Sclerosis
558 Patients Enrolled for Multiple Sclerosis
Nancy E Mayo, PhDPrincipal InvestigatorMcGill University
5 Previous Clinical Trials
450 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~19 spots leftby May 2025